Cargando…

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors

PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses in multiple malignancies, we explored whether p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Yu, Bi, Wenya Linda, Greenwald, Noah F., Du, Ziming, Agar, Nathalie Y. R., Kaiser, Ursula B., Woodmansee, Whitney W., Reardon, David A., Freeman, Gordon J., Fecci, Peter E., Laws, Edward R., Santagata, Sandro, Dunn, Gavin P., Dunn, Ian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363530/ https://www.ncbi.nlm.nih.gov/pubmed/27655724 http://dx.doi.org/10.18632/oncotarget.12088

Ejemplares similares

Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling
por: Mei, Yu, et al.
Publicado: (2017)

Perioperative Management of Patients Undergoing Transsphenoidal Pituitary Surgery
por: Zada, Gabriel, et al.
Publicado: (2010)

Genomic profile of human meningioma cell lines
por: Mei, Yu, et al.
Publicado: (2017)

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
por: Du, Ziming, et al.
Publicado: (2014)

SUN-420 Pituitary Apoplexy Associated With Apixaban
por: Fanous, Nada, et al.
Publicado: (2019)

The Epigenomics of Pituitary Adenoma
por: Hauser, Blake M., et al.
Publicado: (2019)

MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma
por: Miller, Michael B., et al.
Publicado: (2016)

GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors
por: Fu, Yujie, et al.
Publicado: (2020)

Erratum: Genomic landscape of high-grade meningiomas
por: Bi, Wenya Linda, et al.
Publicado: (2017)

Genomic landscape of high-grade meningiomas
por: Bi, Wenya Linda, et al.
Publicado: (2017)

PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
por: Cossu, Giulia, et al.
Publicado: (2023)

Checkpoint blockade therapy for functioning pituitary adenomas
por: Lorrey, Selena J., et al.
Publicado: (2020)

Cyst Type Differentiates Rathke Cleft Cysts From Cystic Pituitary Adenomas
por: Tavakol, Sherwin, et al.
Publicado: (2021)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Editorial: It takes a village: The expanding multi-disciplinary approach to brain metastasis
por: Fecci, Peter E., et al.
Publicado: (2022)

Management of intracranial melanomas in the era of precision medicine
por: Young, Grace J., et al.
Publicado: (2017)

Radiographic prediction of meningioma grade by semantic and radiomic features
por: Coroller, Thibaud P., et al.
Publicado: (2017)

PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway
por: Mirzaei, Reza, et al.
Publicado: (2021)

Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
por: Salvatori, Roberto, et al.
Publicado: (2013)

Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement
por: Casanueva, Felipe F., et al.
Publicado: (2017)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

OR20-04 Genetic Profiling Using A Gene Panel Identifies Pathogenic Variants And Copy Number Variations In Pituitary Adenomas
por: Silva, Ticiana, et al.
Publicado: (2023)

OR23-03 Post-Operative Day One Morning Cortisol Value as a Biomarker to Predict the Recurrence of Cushing Disease
por: Wang, Fang, et al.
Publicado: (2020)

A molecularly integrated grade for meningioma
por: Driver, Joseph, et al.
Publicado: (2021)

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
por: Khan, Saad M, et al.
Publicado: (2022)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
por: Karimi, Shirin, et al.
Publicado: (2021)

The NETting of pituitary adenoma: a gland illusion
por: Ho, Ken K. Y., et al.
Publicado: (2022)

Pseudo-Cerebrospinal Fluid Rhinorrhea Resulting from Aberrant Cross-Innervation of Trigeminal and Facial Nerves following Skull Base Surgery
por: Grannan, Benjamin L., et al.
Publicado: (2015)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

MON-287 Expression of Programmed Death-Ligand 1 (PD-L1) in Human Pituitary Neuroendocrine Tumor
por: Suteau, Valentine, et al.
Publicado: (2020)

SAT-250 A Case of Late Recurrent Cushing’s Disease Presenting with Proximal Myopathy
por: Barsamyan, Gayane, et al.
Publicado: (2020)

Dramatic response to targeted therapy in an aggressive olfactory neuroblastoma: illustrative case
por: Gupta, Saksham, et al.
Publicado: (2022)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

The drinking water contaminant dibromoacetonitrile delays G1-S transition and suppresses Chk1 activation at broken replication forks
por: Caspari, Thomas, et al.
Publicado: (2017)

Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis
por: Cello, Gregory, et al.
Publicado: (2023)

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
por: Färkkilä, Anniina, et al.
Publicado: (2020)

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas
por: Cryan, Jane B., et al.
Publicado: (2014)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hb81ptqgcpm7cf65c2l8795fcc